Perspective Therapeutics, Inc.
CATX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000728387
In the last 90 days, Perspective Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 131 institutions reported holding it in 13F filings for Q2 2026, worth $297.6M in total; no superinvestor holds it.
Holders of 5% or more of CATX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Perspective Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Commodore Capital LP | 13G | 9.90%11.9M shares | New | Feb 9, 20261 filing | Feb 9, 2026 | SEC |
| TCG Crossover GP II, LLC | 13G | 6.90%7.92M shares | New | Feb 6, 20261 filing | Feb 6, 2026 | SEC |
| Qatar Investment Authority | 13G | 6.20%7.07M shares | New | Feb 5, 20261 filing | Feb 5, 2026 | SEC |
| Morgan Stanley | 13G | 6.00%4.46M shares | New | Feb 12, 20261 filing | Feb 12, 2026 | SEC |
| Johnson Frances | 13G/A | 5.90%16.8M shares | – | Feb 5, 20241 filing | Feb 5, 2024 | SEC |
| Schultz Michael K | 13G/A | 5.90%16.8M shares | – | Feb 5, 20241 filing | Feb 5, 2024 | SEC |
| Avidity Partners Management LP | 13G | 5.30%6.05M shares | +1.10 ppfrom 4.20% | Feb 14, 20252 filings | Mar 10, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
12 Schedule 13D and 13G filings on Perspective Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jun 30, 20265:36 PM ET | Millennium Management LLCand 2 others | 13G | 4.30%4.89M shares | NewBelow 5% | Jun 23, 2026 | SEC |
| Mar 10, 20268:36 PM ET | Avidity Partners Management LPand 5 others | 13G | 5.30%6.05M shares | +1.10 ppfrom 4.20% | Feb 20, 2026 | SEC |
| Feb 12, 202610:50 AM ET | Morgan Stanley | 13G | 6.00%4.46M shares | New | Dec 31, 2025 | SEC |
| Feb 9, 20264:40 PM ET | Commodore Capital LPand 3 others | 13G | 9.90%11.9M shares | New | Feb 2, 2026 | SEC |
| Feb 6, 20264:45 PM ET | TCG Crossover GP II, LLCand 4 others | 13G | 6.90%7.92M shares | New | Feb 3, 2026 | SEC |
| Feb 5, 20268:48 AM ET | Qatar Investment Authority | 13G | 6.20%7.07M shares | New | Feb 4, 2026 | SEC |
| Dec 5, 20252:03 PM ET | FMR LLCand 1 other | 13G/A | 0.40%312.2K shares | −7.80 ppfrom 8.20%Below 5% | Nov 28, 2025 | SEC |
| Nov 7, 202511:13 AM ET | FMR LLCand 1 other | 13G/A | 8.20%6.06M shares | – | Oct 31, 2025 | SEC |
| Feb 14, 202511:37 AM ET | Janus Henderson Group PLC | 13G/A | 0.00%17.8K shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 14, 202510:26 AM ET | Avidity Partners Management LPand 5 others | 13G/A | 4.20%2.84M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 5, 20247:18 PM ET | Johnson Frances | 13G/A | 5.90%16.8M shares | – | Dec 31, 2023 | SEC |
| Feb 5, 20245:35 PM ET | Schultz Michael K | 13G/A | 5.90%16.8M shares | – | Dec 31, 2023 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Perspective Therapeutics, Inc. shares.
No Form 144 notices for Perspective Therapeutics, Inc. are on file.